Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma Today 9:45 AM ET (GlobeNewswire)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.